论文部分内容阅读
目的观察华蟾素注射液联合多西他赛单药化疗治疗高龄晚期非小细胞肺癌的临床疗效。方法高龄晚期非小细胞肺癌患者76例,分为联合治疗组46例及单纯化疗组30例。2组均采用多西他赛单药方案,联合治疗组加用华蟾素注射液联合静脉滴注,完成2周期后,评价疗效及不良反应。结果联合治疗组总有效率(30.4%)与单纯化疗组(33.3%)比较,差异无统计学意义;联合治疗组生活质量提高率(45.7%)明显高于单纯化疗组(23.3%),差异有统计学意义,而2组在稳定率及生活质量下降率方面差异无统计学意义;联合治疗组的Ⅲ/Ⅳ度不良反应发生率均低于单纯化疗组。结论华蟾素注射液联合多西他赛单药化疗治疗高龄晚期非小细胞肺癌能明显改善临床症状,减轻化疗毒副反应,从而提高生活质量,值得临床推广应用。
Objective To observe the clinical efficacy of Huachansu injection combined with docetaxel single-agent chemotherapy in the treatment of advanced non-small cell lung cancer. Methods Seventy-six patients with advanced non-small cell lung cancer were divided into two groups: the combination therapy group (46 cases) and the chemotherapy alone group (30 cases). The docetaxel single-agent regimen was used in both groups, and the combined treatment group was additionally treated with intravenous injection of Huachansu injection. After 2 cycles were completed, the efficacy and adverse reactions were evaluated. Results There was no significant difference in the total effective rate (30.4%) between the combination therapy group and the chemotherapy alone group (33.3%); the improvement rate of the quality of life (45.7%) was significantly higher in the combination therapy group than in the chemotherapy alone group (23.3%). There was statistical significance, but there was no significant difference in stability rate and rate of decline of quality of life between the two groups; the incidence of adverse effects of III/IV was lower in the combined treatment group than in the chemotherapy alone group. Conclusion Huachansu injection combined with docetaxel single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer can significantly improve the clinical symptoms, reduce the toxicity of chemotherapy, thereby improving the quality of life, it is worthy of clinical application.